XLV flat as rates and mega-cap pharma/insurer cross-currents offset each other
XLV•XLV was essentially unchanged at about $145.31 as investors balanced higher-rate macro pressures with mixed, stock-specific healthcare headlines. The ETF is dominated by mega-cap pharma and managed-care names, so moves in Eli Lilly, Johnson & Johnson, AbbVie, Merck, and UnitedHealth tend to drive day-to-day performance.
1. What XLV is and what it tracks
The State Street Health Care Select Sector SPDR ETF (XLV) seeks to match (before fees and expenses) the price and yield performance of the Health Care Select Sector Index, giving large-cap, S&P 500-style U.S. healthcare exposure. Its portfolio is top-heavy in mega-cap healthcare—recent holdings data show Eli Lilly and Johnson & Johnson as the two largest positions, followed by AbbVie, Merck, and UnitedHealth—so a handful of names can explain much of the ETF’s daily move. (ssga.com)
